Adalimumab-aaty (1 Pen) Coupons & Savings Card – Discount Prices from $530.72
My prescription
Edit
40MG/0.4ML, Adalimumab-aaty (1 Pen) (1 Auto-injector Kit)
Select pharmacy
Walgreens
$530.72
COUPON PRICE
Albertsons
$532.65
COUPON PRICE
Walmart
$546.13
COUPON PRICEAdalimumab-aaty (1 Pen) savings card
Show this card to your pharmacistWalgreens
$530.72
BIN
ID
PCN
GRP
019876
LH0C78EBCC
CHIPPO
LHX
Powered by
Price history for Adalimumab-aaty (1 Pen) (generic)
1, 40MG/0.4ML
Average retail price for Adalimumab-aaty (1 Pen)
Average SaveHealth price for Adalimumab-aaty (1 Pen)
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
We analyzed Adalimumab-aaty (1 Pen) prices for (40MG/0.4ML, 1 Auto-injector Kit) over the last 12 months. The average retail price was $1780.08, while the average price using the SaveHealth discount card was $537.38. That's a savings of approximately 69.81% when using our Adalimumab-aaty (1 Pen) coupon.
Adalimumab-aaty (1 Pen) dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 40MG/0.4ML | 1 Auto-injector Kit | $530.72 | $530.72 |
| 80MG/0.8ML | 1 Auto-injector Kit | $530.72 | $530.72 |
Adalimumab-aaty (1 Pen) Warnings
When considering the use of the Adalimumab-aaty 1 Pen, it's important to be aware of several potential risks associated with its administration:
Serious Infections: This medication can lower your body's ability to fight infections, increasing the risk of serious infections such as tuberculosis (TB). Before starting treatment, your doctor may test you for TB and monitor you for signs of infection during therapy. If you develop symptoms like fever, cough, or unexplained weight loss, inform your healthcare provider promptly.
Cancer Risk: There have been reports of certain types of cancer, including lymphoma and leukemia, in patients using TNF blockers like Adalimumab-aaty. Some cases have been fatal, particularly in children, adolescents, and young adults. Discuss any concerns about cancer risk with your doctor.
Allergic Reactions: Severe allergic reactions, including anaphylaxis and angioedema, have occurred with this medication. Symptoms may include difficulty breathing, swelling of the face or throat, and hives. Seek immediate medical attention if you experience any signs of a serious allergic reaction.
Hepatitis B Reactivation: If you are a carrier of hepatitis B virus (HBV), using Adalimumab-aaty may cause the virus to become active again, which can lead to serious liver problems. Your doctor should screen you for HBV before starting treatment and monitor you during therapy.
Nervous System Disorders: There have been rare cases of new or worsening nervous system disorders, such as multiple sclerosis or Guillain-Barré syndrome, in patients using TNF blockers. If you experience symptoms like vision changes, muscle weakness, or numbness, contact your healthcare provider.
Blood Disorders: Some patients have developed blood problems, including decreased blood cell counts, which can lead to serious health issues. Symptoms may include persistent fever, bruising, or pale skin. Inform your doctor if you notice any of these signs.
Heart Failure: Worsening or new onset of heart failure has been reported in patients using TNF blockers. If you have heart failure or are at risk, your doctor will monitor you closely during treatment.
Autoimmune Reactions: In rare cases, treatment with Adalimumab-aaty may lead to the development of lupus-like symptoms, such as chest discomfort, shortness of breath, joint pain, or a rash on your cheeks or arms that worsens with sun exposure. If these occur, contact your healthcare provider.
Vaccinations: Avoid live vaccines while using Adalimumab-aaty, as they may increase the risk of infections. Ensure your vaccinations are up to date before starting treatment.
It's crucial to discuss these risks with your healthcare provider to determine if Adalimumab-aaty is appropriate for you and to establish a monitoring plan during treatment.
Adalimumab-aaty (1 Pen) Side Effects
When using the Adalimumab-Aaty 1 Pen, it's important to be aware of potential side effects. Common reactions at the injection site include redness, itching, pain, or swelling. These symptoms are usually mild and temporary. To minimize discomfort, allow the pen to reach room temperature for 15 to 30 minutes before injecting, and rotate injection sites with each dose. Some individuals may experience mild infections of the nose, throat, or sinuses, as well as headaches, stomach discomfort, or muscle and bone pain. These side effects are generally manageable and should be discussed with your healthcare provider if they persist or worsen. Serious side effects, though less common, require immediate medical attention. These include signs of severe infections such as persistent fever, chills, night sweats, or difficulty breathing; symptoms of heart failure like shortness of breath or swelling in the ankles or feet; indications of liver problems such as yellowing of the skin or eyes, dark urine, or persistent nausea; and neurological issues like numbness, tingling, vision changes, or muscle weakness. Rarely, severe allergic reactions may occur, characterized by hives, swelling of the face, lips, or tongue, and difficulty breathing. If you experience any of these symptoms, seek emergency medical care immediately. Always inform your healthcare provider about any side effects you experience while using Adalimumab-Aaty. They can provide guidance on managing side effects and determine if any adjustments to your treatment are necessary.
Adalimumab-aaty (1 Pen) Interactions
When using the Adalimumab-aaty 1 Pen, it's important to be aware of potential interactions with other medications and vaccines:
Biologic Medications: Combining Adalimumab-aaty with other biologic drugs, such as anakinra or abatacept, is not recommended. This combination can increase the risk of serious infections without providing additional therapeutic benefits. Similarly, using Adalimumab-aaty alongside other tumor necrosis factor (TNF) blockers like etanercept or infliximab may elevate infection risks.
Methotrexate: Adalimumab-aaty can be used with methotrexate, a common treatment for rheumatoid arthritis. While methotrexate may reduce the clearance of Adalimumab-aaty from the body, no dosage adjustments are typically necessary for either medication.
Live Vaccines: Avoid receiving live vaccines while on Adalimumab-aaty, as they can increase the risk of infections. Before starting treatment, ensure that all vaccinations are up to date. Inactivated vaccines are generally safe but may be less effective during therapy.
Other Medications: Inform your healthcare provider about all medications you're taking, including over-the-counter drugs and supplements. Certain medications, such as Cyclosporine or Theophylline, may require careful monitoring when used with Adalimumab-aaty.
Always consult your healthcare provider before starting or stopping any medications while using Adalimumab-aaty to ensure safe and effective treatment.
What is the difference between adalimumab and Humira?
Adalimumab is the generic name for the medication, while Humira is the brand name. Both refer to the same drug, which is used to treat various autoimmune conditions.
How long can you stay on adalimumab?
The duration for which a patient can stay on adalimumab varies depending on the individual's condition and response to the medication. Many patients use adalimumab as a long-term treatment under the guidance of their healthcare provider. It is important for patients to have regular follow-ups with their healthcare provider to monitor the effectiveness and any potential side effects of the medication. The decision to continue or discontinue adalimumab should always be made in consultation with a healthcare professional.
Is adalimumab the same as Humira?
Yes, adalimumab is the generic name for the brand name drug Humira. They are the same medication.
Who should not take adalimumab?
Individuals who should not take adalimumab include those with a known hypersensitivity to adalimumab or any of its components. Additionally, it is generally not recommended for individuals with active infections, such as tuberculosis or other severe infections, due to the risk of exacerbating these conditions. Patients with a history of recurrent infections or underlying conditions that predispose them to infections should use adalimumab with caution. It is important for individuals to consult with their healthcare provider to determine if adalimumab is appropriate for their specific medical condition.
What are the long-term effects of adalimumab?
Long-term use of adalimumab can lead to several potential effects. Patients may experience an increased risk of infections due to the suppression of the immune system. There is also a potential for the development of certain types of cancers, such as lymphoma and skin cancer. Other possible long-term effects include liver damage, heart failure, and the development of autoimmune conditions like lupus-like syndrome. Regular monitoring by a healthcare provider is essential to manage these risks effectively.